Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Editorials |5 May 2015

Screening and Treating Subclinical Thyroid Disease: Getting Past the Impasse Free

Anne R. Cappola, MD, ScM; David S. Cooper, MD

Anne R. Cappola, MD, ScM
From Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, and The Johns Hopkins University School of Medicine, Baltimore, Maryland.

David S. Cooper, MD
From Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, and The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published online first at www.annals.org on 24 March 2015.
  • From Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, and The Johns Hopkins University School of Medicine, Baltimore, Maryland.

    Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0640.

    Requests for Single Reprints: David S. Cooper, MD, Division of Endocrinology, Diabetes, & Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287; e-mail, dscooper@jhmi.edu.

    Current Author Addresses:Dr. Cappola: Perelman School of Medicine at the University of Pennsylvania, 718 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021.

    Dr. Cooper: Division of Endocrinology, Diabetes, & Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link
Thyroid dysfunction is common, and both insufficient and excess thyroid hormone can cause myriad systemic effects resulting in symptoms and, in extreme cases, serious illness and even death. There are sensitive and specific blood tests to diagnose thyroid dysfunction and readily available therapies to treat it. This supports the potential utility of screening.
In this issue, the U.S. Preventive Services Task Force (USPSTF) presents its findings on screening for thyroid dysfunction (1). Not surprisingly, the USPSTF concluded that evidence is insufficient to assess the balance of potential benefits and harms of screening nonpregnant adults. This conclusion is based on the absence of large prospective randomized, controlled trials (RCTs) demonstrating a benefit of treatment of subclinical hypothyroidism or subclinical hyperthyroidism (2). Indeed, the recommendation is similar to the one made by the USPSTF in 2004 (3), and it is disheartening to see that so little progress seems to have been made in trying to address this important clinical problem.
This leaves the health care provider and the patient in a familiar vacuum of management using the imperfect data available. The current USPSTF statement provides a useful summary of the few short-term clinical trials and highlights the disappointingly small number of new RCTs since the last report, with no trials conducted in the United States. However, it fails to acknowledge the publication in the intervening period of 3 individual-patient data meta-analyses of observational studies (4–6). These meta-analyses provide important information about potential risks from untreated subclinical thyroid dysfunction and support a dose–response relationship between thyroid-stimulating hormone (TSH) concentrations at either extreme and an increased risk for cardiovascular events and death. They also support potential serum TSH thresholds for increased risk of less than 0.45 and greater than 7 mIU/L and more confident thresholds of less than 0.1 and greater than 10 mIU/L, although the benefits and harms of treatment at these thresholds have not been defined in RCTs.
We agree that the first step in moving from a recommendation of “insufficient evidence” to a more clinically useful recommendation requires data from RCTs with hard end points. Although an effort to fund a U.S. trial in subclinical hypothyroidism was unsuccessful, the European TRUST (Thyroid Hormone Replacement for Subclinical Hypothyroidism) study is currently under way (www.clinicaltrials.gov/ct2/show/NCT01660126?term=TRUST+trial&rank=1). Two European trials designed to examine treatment of subclinical hyperthyroidism failed to complete recruitment due to the lower prevalence of the condition and were terminated. Therefore, there is little hope of data on the risks and benefits of treating this condition. Subclinical hyperthyroidism is associated with atrial fibrillation, congestive heart failure, and osteoporosis in older persons and postmenopausal women (7). These are precisely the unfavorable health effects seen in older persons with overt hyperthyroidism, which is why professional groups recommend treating subclinical hyperthyroidism in these vulnerable populations, especially those with serum TSH concentrations less than 0.1 mIU/L (8).
As practicing endocrinologists, we find 2 themes in the USPSTF statement troublesome. The first is the reference to “measurement variability” of serum TSH. This variability is not due to poor assay performance but to inherent biological variability related to the exquisite sensitivity of the hypothalamic–pituitary–thyroid axis to even minimal perturbations in thyroid secretion. Superimposed on these clinically insignificant changes are potential episodes of silent thyroiditis and systemic illness. This is the reason for confirming the persistence of a serum TSH abnormality with a single repeated measurement several months later. The rationale in the USPSTF statement for “[m]ultiple tests … over a 3- to 6-month interval” is neither biologically relevant nor supported by data.
The second disturbing issue in the USPSTF statement is the use of the term “asymptomatic” in the context of thyroid dysfunction. By definition, a patient with symptoms of fatigue, hair loss, or palpitations who has a TSH test done is undergoing “case finding,” not screening. It is hard to justify withholding TSH testing in a patient who does not have an obvious alternative cause for any of these symptoms. The clinical conundrum arises when a patient with any of the nonspecific symptoms of thyroid dysfunction has test results consistent with subclinical thyroid dysfunction. Were the patient's symptoms due to a mild thyroid problem, or is there an unrelated biochemical abnormality that may or may not be clinically significant? The effectiveness of treatment of either type of subclinical thyroid dysfunction in reversing the symptoms that triggered testing has never been evaluated in placebo-controlled trials. Therefore, it is not clear that the management of a symptomatic patient with subclinical thyroid dysfunction should differ from that of an asymptomatic patient, given the potential for beneficial effects on cardiovascular outcomes and bone health, which might occur with therapy even in asymptomatic persons.
We also reiterate concerns expressed in the public comment section of the USPSTF statement about not treating asymptomatic overt thyroid disease (defined by serum concentrations of free thyroxine or triiodothyronine that are outside their reference ranges), as would occur in the placebo group of an RCT. The implicit suggestion that there would only be benefit to treating symptomatic overt thyroid disease shows how far astray one can go in pursuit of the “holy grail” of the RCT. This is particularly concerning in elderly adults, in whom symptoms are often absent and atypical symptoms may prevail (9). We strongly disagree with the proposal to conduct treatment trials of asymptomatic overt thyroid dysfunction. In the case of overt hypothyroidism, treatment with levothyroxine is recommended, and patients with overt hyperthyroidism are treated with antithyroid medications, radioiodine, or surgery, depending on the clinical circumstances and patient preference. There should be no debate about this.
We hope that when the USPSTF evaluates screening for thyroid dysfunction in another 10 years, there will be additional RCT data to provide guidance. We agree that these data are urgently needed and call on researchers and funding agencies to partner to make this happen. However, without definitive information—and this is highly probable for subclinical hyperthyroidism—we will need to continue to rely on lower-quality evidence to make important clinical decisions that, admittedly, have the potential to both help and harm patients. The decades-long impasse only enhances the importance of evidence-based clinical practice guidelines designed to assist clinicians in making the best decisions for their patients (8, 10).

References

  1. LeFevre
    Michael L.
    .  
    U.S. Preventive Services Task Force
    Screening for Thyroid Dysfunction: U.S. Preventive Services Task Force Recommendation Statement.
    Ann Intern Med
    2015
    162
    9
    641
    650
    CrossRef
    PubMed
  2. Rugge
    JB
    ,  
    Bougatsos
    C
    ,  
    Chou
    R
    .  
    Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force.
    Ann Intern Med
    2015
    162
    35
    45
    CrossRef
    PubMed
  3. Helfand
    M
    .  
    U.S. Preventive Services Task Force
    Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force.
    Ann Intern Med
    2004
    140
    128
    41
    CrossRef
    PubMed
  4. Rodondi
    N
    ,  
    denElzen
    WP
    ,  
    Bauer
    DC
    ,  
    Cappola
    AR
    ,  
    Razvi
    S
    ,  
    Walsh
    JP
    .  
    et al
    Thyroid Studies Collaboration
    Subclinical hypothyroidism and the risk of coronary heart disease and mortality.
    JAMA
    2010
    304
    1365
    74
    PubMed
    CrossRef
    PubMed
  5. Collet
    TH
    ,  
    Gussekloo
    J
    ,  
    Bauer
    DC
    ,  
    denElzen
    WP
    ,  
    Cappola
    AR
    ,  
    Balmer
    P
    .  
    et al
    Thyroid Studies Collaboration
    Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.
    Arch Intern Med
    2012
    172
    799
    809
    PubMed
    CrossRef
    PubMed
  6. Gencer
    B
    ,  
    Collet
    TH
    ,  
    Virgini
    V
    ,  
    Bauer
    DC
    ,  
    Gussekloo
    J
    ,  
    Cappola
    AR
    .  
    et al
    Thyroid Studies Collaboration
    Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts.
    Circulation
    2012
    126
    1040
    9
    PubMed
    CrossRef
    PubMed
  7. Cooper
    DS
    ,  
    Biondi
    B
    .  
    Subclinical thyroid disease.
    Lancet
    2012
    379
    1142
    54
    PubMed
    CrossRef
    PubMed
  8. Bahn
    RS
    ,  
    Burch
    HB
    ,  
    Cooper
    DS
    ,  
    Garber
    JR
    ,  
    Greenlee
    MC
    ,  
    Klein
    I
    .  
    et al
    American Thyroid Association
    Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.
    Endocr Pract
    2011
    17
    456
    520
    PubMed
    CrossRef
    PubMed
  9. Boelaert
    K
    ,  
    Torlinska
    B
    ,  
    Holder
    RL
    ,  
    Franklyn
    JA
    .  
    Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study.
    J Clin Endocrinol Metab
    2010
    95
    2715
    26
    PubMed
    CrossRef
    PubMed
  10. Jonklaas
    J
    ,  
    Bianco
    AC
    ,  
    Bauer
    AJ
    ,  
    Burman
    KD
    ,  
    Cappola
    AR
    ,  
    Celi
    FS
    .  
    etal
    Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement.
    Thyroid
    2014
    24
    1670
    751
    PubMed
    CrossRef
    PubMed
This article was published online first at www.annals.org on 24 March 2015.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Cappola AR, Cooper DS. Screening and Treating Subclinical Thyroid Disease: Getting Past the Impasse. Ann Intern Med. ;162:664–665. doi: 10.7326/M15-0640

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2015;162(9):664-665.

DOI: 10.7326/M15-0640

2 Citations

See Also

Screening for Thyroid Dysfunction: U.S. Preventive Services Task Force Recommendation Statement
View MoreView Less

Related Articles

Should We Treat for Subclinical Hypothyroidism?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Annals of Internal Medicine; 164 (11): 764-770
Annals for Educators - 6 November 2018
Annals of Internal Medicine; 169 (9): ED9
When Centers for Medicare & Medicaid Services Treats Throat Cancer Like Pharyngitis
Annals of Internal Medicine; 169 (8): 573-574
Much Choice, Much Confusion: Treating Basal Cell Carcinoma
Annals of Internal Medicine; 169 (7): 500-501
View MoreView Less

Journal Club

Guided early deescalation of antiplatelet treatment was noninferior to usual prasugrel care in PCI-treated ACS
Annals of Internal Medicine; 167 (12): JC69
Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non–insulin-treated type 2 diabetes
Annals of Internal Medicine; 167 (8): JC46
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c
Annals of Internal Medicine; 165 (8): JC40
View MoreView Less

Related Point of Care

Palliative Care
Annals of Internal Medicine; 168 (5): ITC33-ITC48
Clostridioides difficile Infection
Annals of Internal Medicine; 169 (7): ITC49-ITC64
Systemic Lupus Erythematosus
Annals of Internal Medicine; 159 (7): ITC4-1
Polymyalgia Rheumatica
Annals of Internal Medicine; 166 (9): ITC65-ITC80
View MoreView Less

Related Topics

Endocrine and Metabolism
Thyroid Disorders

Endocrine and Metabolism, Thyroid Disorders.

PubMed Articles

Immunological aspects of autoimmune thyroid disease - Complex interplay between cells and cytokines.
Cytokine 2019;
Socioeconomic status of the population - a prime determinant in evaluating iodine nutritional status even in a post salt iodization scenario.
J Pediatr Endocrinol Metab 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×